drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01114 | DB01156 | 272 | 593 | [
"DDInter362",
"DDInter252"
] | Chlorpheniramine | Bupropion | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
272,
24,
593
]
],
[
[
272,
6,
8374
],
[
8374,
45,
593
]
],
[
[
272,
18,
3741
],
[
3741,
57,
593
]
],
[
[
272,
21,
29243
],
[
29243,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Chlorpheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Chlorpheniramine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Bupropion (Compound)
Chlorpheniramine (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Bupropion ... |
DB05015 | DB10429 | 1,077 | 200 | [
"DDInter174",
"DDInter282"
] | Belinostat | Candida albicans | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1077,
24,
200
]
],
[
[
1077,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1077,
25,
976
],
[
976,
24,
200
]
],
[
[
1077,
63,
869
],
[
869,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Belinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ... |
DB00853 | DB10276 | 1,686 | 1,624 | [
"DDInter1762",
"DDInter1623"
] | Temozolomide | Rotavirus vaccine | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1686,
25,
1624
]
],
[
[
1686,
24,
1307
],
[
1307,
25,
1624
]
],
[
[
1686,
63,
1648
],
[
1648,
25,
1624
]
],
[
[
1686,
25,
770
],
[
770... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may lead to a major life threatening interaction when taken with Rotavirus vaccine
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin... |
DB06605 | DB10344 | 1,409 | 992 | [
"DDInter108",
"DDInter818"
] | Apixaban | Ginger | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1409,
24,
992
]
],
[
[
1409,
64,
1578
],
[
1578,
24,
992
]
],
[
[
1409,
25,
1421
],
[
1421,
63,
992
]
],
[
[
1409,
24,
1297
],
[
1297,... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"... | Apixaban may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Apixaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction th... |
DB06210 | DB11793 | 72 | 738 | [
"DDInter631",
"DDInter1297"
] | Eltrombopag | Niraparib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
72,
24,
738
]
],
[
[
72,
24,
466
],
[
466,
63,
738
]
],
[
[
72,
63,
663
],
[
663,
24,
738
]
],
[
[
72,
64,
367
],
[
367,
24,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and... |
DB00835 | DB01149 | 100 | 851 | [
"DDInter245",
"DDInter1274"
] | Brompheniramine | Nefazodone | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
100,
24,
851
]
],
[
[
100,
63,
252
],
[
252,
40,
851
]
],
[
[
100,
63,
1178
],
[
1178,
1,
851
]
],
[
[
100,
24,
673
],
[
673,
40... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles ... |
DB01215 | DB08912 | 1,418 | 1,040 | [
"DDInter677",
"DDInter462"
] | Estazolam | Dabrafenib | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1418,
24,
1040
]
],
[
[
1418,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
1418,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1418,
63,
608
],
[
60... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Estazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Estazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Estazolam (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine an... |
DB00557 | DB11730 | 252 | 351 | [
"DDInter895",
"DDInter1588"
] | Hydroxyzine | Ribociclib | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
252,
25,
351
]
],
[
[
252,
23,
112
],
[
112,
23,
351
]
],
[
[
252,
24,
222
],
[
222,
23,
351
]
],
[
[
252,
24,
355
],
[
355,
24,... | [
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and S... |
DB00041 | DB00108 | 1,648 | 1,066 | [
"DDInter38",
"DDInter1268"
] | Aldesleukin | Natalizumab | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Major | 2 | [
[
[
1648,
25,
1066
]
],
[
[
1648,
24,
949
],
[
949,
63,
1066
]
],
[
[
1648,
25,
375
],
[
375,
64,
1066
]
],
[
[
1648,
24,
1488
],
[
1488,
... | [
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Natalizumab
Aldesleuki... |
DB00916 | DB08875 | 112 | 1,618 | [
"DDInter1202",
"DDInter262"
] | Metronidazole | Cabozantinib | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Minor | 0 | [
[
[
112,
23,
1618
]
],
[
[
112,
23,
1247
],
[
1247,
23,
1618
]
],
[
[
112,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
112,
62,
867
],
[
867,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Picos... |
DB00059 | DB00697 | 1,560 | 876 | [
"DDInter1404",
"DDInter1821"
] | Pegaspargase | Tizanidine | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
1560,
24,
876
]
],
[
[
1560,
25,
770
],
[
770,
63,
876
]
],
[
[
1560,
24,
1374
],
[
1374,
63,
876
]
],
[
[
1560,
24,
912
],
[
912,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thali... | Pegaspargase may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone ma... |
DB01232 | DB06176 | 1,327 | 1,342 | [
"DDInter1640",
"DDInter1616"
] | Saquinavir | Romidepsin | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
1327,
25,
1342
]
],
[
[
1327,
62,
112
],
[
112,
23,
1342
]
],
[
[
1327,
64,
485
],
[
485,
24,
1342
]
],
[
[
1327,
25,
1616
],
[
1616,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Saquinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Saquinavir may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may ca... |
DB05812 | DB08881 | 1,374 | 868 | [
"DDInter8",
"DDInter1925"
] | Abiraterone | Vemurafenib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1374,
25,
868
]
],
[
[
1374,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1374,
21,
29106
],
[
29106,
60,
868
]
],
[
[
1374,
62,
211
],
[
211,
... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Abiraterone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Abiraterone (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolt... |
DB00010 | DB01067 | 1,649 | 959 | [
"DDInter1661",
"DDInter826"
] | Sermorelin | Glipizide | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1649,
24,
959
]
],
[
[
1649,
24,
245
],
[
245,
40,
959
]
],
[
[
1649,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1649,
24,
433
],
[
433,
... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB01403 | DB09043 | 9 | 135 | [
"DDInter1175",
"DDInter36"
] | Methotrimeprazine | Albiglutide | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
9,
24,
135
]
],
[
[
9,
63,
1647
],
[
1647,
23,
135
]
],
[
[
9,
63,
176
],
[
176,
24,
135
]
],
[
[
9,
1,
820
],
[
820,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glar... |
DB06810 | DB15233 | 397 | 1,650 | [
"DDInter1484",
"DDInter142"
] | Plicamycin | Avapritinib | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
397,
25,
1650
]
],
[
[
397,
63,
1257
],
[
1257,
24,
1650
]
],
[
[
397,
24,
270
],
[
270,
24,
1650
]
],
[
[
397,
64,
908
],
[
908,
... | [
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
[
"Pegfil... | Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab an... |
DB08826 | DB09407 | 1,292 | 853 | [
"DDInter489",
"DDInter1114"
] | Deferiprone | Magnesium chloride | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1292,
24,
853
]
],
[
[
1292,
63,
544
],
[
544,
24,
853
]
],
[
[
1292,
24,
460
],
[
460,
63,
853
]
],
[
[
1292,
24,
286
],
[
286,
... | [
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00374 | DB00852 | 1,061 | 1,445 | [
"DDInter1852",
"DDInter1545"
] | Treprostinil | Pseudoephedrine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Moderate | 1 | [
[
[
1061,
24,
1445
]
],
[
[
1061,
24,
22
],
[
22,
40,
1445
]
],
[
[
1061,
18,
3576
],
[
3576,
45,
1445
]
],
[
[
1061,
18,
1954
],
[
1954,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Pseudoephedrine (Compound)
Treprostinil (Compound) downregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Pseudoephedrine (Compound)
Treprostinil (Compound) downregulates COG2 (Gene... |
DB06779 | DB08886 | 365 | 637 | [
"DDInter470",
"DDInter126"
] | Dalteparin | Asparaginase Erwinia chrysanthemi | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
365,
24,
637
]
],
[
[
365,
64,
1479
],
[
1479,
24,
637
]
],
[
[
365,
25,
1421
],
[
1421,
63,
637
]
],
[
[
365,
24,
1496
],
[
1496,
... | [
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic aci... | Dalteparin may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dalteparin may lead to a major life threatening interaction when taken with Betrixab... |
DB00533 | DB01082 | 1,416 | 1,448 | [
"DDInter1613",
"DDInter1713"
] | Rofecoxib | Streptomycin | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
1416,
24,
1448
]
],
[
[
1416,
24,
1272
],
[
1272,
63,
1448
]
],
[
[
1416,
63,
91
],
[
91,
24,
1448
]
],
[
[
1416,
24,
1479
],
[
1479,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vanc... |
DB08885 | DB11627 | 363 | 1,367 | [
"DDInter33",
"DDInter860"
] | Aflibercept | Hepatitis B Vaccine (Recombinant) | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
363,
24,
1367
]
],
[
[
363,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
363,
63,
259
],
[
259,
24,
1367
]
],
[
[
363,
25,
375
],
[
375,
... | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Aflibercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]... | Aflibercept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept ... |
DB01073 | DB09074 | 1,488 | 1,362 | [
"DDInter745",
"DDInter1327"
] | Fludarabine | Olaparib | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1488,
24,
1362
]
],
[
[
1488,
63,
896
],
[
896,
24,
1362
]
],
[
[
1488,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1488,
24,
385
],
[
385,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekin... |
DB08875 | DB11837 | 1,618 | 1,297 | [
"DDInter262",
"DDInter1351"
] | Cabozantinib | Osilodrostat | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1618,
25,
1297
]
],
[
[
1618,
23,
1135
],
[
1135,
23,
1297
]
],
[
[
1618,
62,
112
],
[
112,
23,
1297
]
],
[
[
1618,
63,
222
],
[
222,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxeg... | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB00056 | DB14711 | 816 | 779 | [
"DDInter814",
"DDInter1680"
] | Gemtuzumab ozogamicin | Smallpox (Vaccinia) Vaccine, Live | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
816,
25,
779
]
],
[
[
816,
25,
1064
],
[
1064,
25,
779
]
],
[
[
816,
24,
1560
],
[
1560,
25,
779
]
],
[
[
816,
25,
676
],
[
676,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
... | Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Pegasp... |
DB00831 | DB00916 | 1,178 | 112 | [
"DDInter1866",
"DDInter1202"
] | Trifluoperazine | Metronidazole | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
1178,
23,
112
]
],
[
[
1178,
21,
28778
],
[
28778,
60,
112
]
],
[
[
1178,
63,
618
],
[
618,
23,
112
]
],
[
[
1178,
1,
827
],
[
827,
... | [
[
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
... | Trifluoperazine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Metronidazole (Compound)
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a minor interaction that can limit clinical effect... |
DB01182 | DB11837 | 371 | 1,297 | [
"DDInter1534",
"DDInter1351"
] | Propafenone | Osilodrostat | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
371,
24,
1297
]
],
[
[
371,
62,
112
],
[
112,
23,
1297
]
],
[
[
371,
23,
466
],
[
466,
62,
1297
]
],
[
[
371,
40,
271
],
[
271,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Propafenone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Propafenone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and ... |
DB00420 | DB01168 | 508 | 1,053 | [
"DDInter1532",
"DDInter1526"
] | Promazine | Procarbazine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
508,
24,
1053
]
],
[
[
508,
18,
4930
],
[
4930,
57,
1053
]
],
[
[
508,
24,
480
],
[
480,
24,
1053
]
],
[
[
508,
40,
9
],
[
9,
63... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Promazine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (C... | Promazine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Procarbazine (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Promaz... |
DB06595 | DB08912 | 1,491 | 1,040 | [
"DDInter1214",
"DDInter462"
] | Midostaurin | Dabrafenib | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1491,
24,
1040
]
],
[
[
1491,
24,
1612
],
[
1612,
62,
1040
]
],
[
[
1491,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
1491,
64,
478
],
[
478... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexa... |
DB00264 | DB00279 | 88 | 1,152 | [
"DDInter1200",
"DDInter1074"
] | Metoprolol | Liothyronine | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Minor | 0 | [
[
[
88,
23,
1152
]
],
[
[
88,
23,
542
],
[
542,
40,
1152
]
],
[
[
88,
6,
4973
],
[
4973,
45,
1152
]
],
[
[
88,
21,
29118
],
[
29118,
... | [
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
]
],
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levothyroxine"
],
[
... | Metoprolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine (Compound) resembles Liothyronine (Compound)
Metoprolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Liothyronine (Compound)
Metoprolol (Compound) causes Tachycardia (Side Effect) and T... |
DB00092 | DB00601 | 58 | 453 | [
"DDInter40",
"DDInter1073"
] | Alefacept | Linezolid | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Moderate | 1 | [
[
[
58,
24,
453
]
],
[
[
58,
24,
792
],
[
792,
1,
453
]
],
[
[
58,
24,
770
],
[
770,
63,
453
]
],
[
[
58,
24,
168
],
[
168,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban (Compound) resembles Linezolid (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that coul... |
DB09030 | DB11652 | 840 | 1,155 | [
"DDInter1945",
"DDInter1891"
] | Vorapaxar | Tucatinib | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
840,
25,
1155
]
],
[
[
840,
63,
222
],
[
222,
23,
1155
]
],
[
[
840,
64,
609
],
[
609,
24,
1155
]
],
[
[
840,
24,
214
],
[
214,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine"... | Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Vorapaxar may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may c... |
DB01075 | DB05812 | 1,376 | 1,374 | [
"DDInter569",
"DDInter8"
] | Diphenhydramine | Abiraterone | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1376,
24,
1374
]
],
[
[
1376,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1376,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
1376,
63,
211
],
[
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (... | Diphenhydramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Diphenhydramine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with To... |
DB01610 | DB04845 | 248 | 309 | [
"DDInter1912",
"DDInter1001"
] | Valganciclovir | Ixabepilone | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
248,
24,
309
]
],
[
[
248,
21,
28736
],
[
28736,
60,
309
]
],
[
[
248,
63,
60
],
[
60,
23,
309
]
],
[
[
248,
63,
1419
],
[
1419,
... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Valganciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Dehydration"
],
[
"Dehydration",
"{u} (Side Ef... | Valganciclovir (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when tak... |
DB00277 | DB01138 | 1,031 | 804 | [
"DDInter1791",
"DDInter1726"
] | Theophylline | Sulfinpyrazone | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Minor | 0 | [
[
[
1031,
23,
804
]
],
[
[
1031,
6,
3486
],
[
3486,
45,
804
]
],
[
[
1031,
24,
629
],
[
629,
24,
804
]
],
[
[
1031,
24,
1297
],
[
1297,
... | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compo... | Theophylline (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfinpyrazone (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Theophyl... |
DB00305 | DB10429 | 377 | 200 | [
"DDInter1232",
"DDInter282"
] | Mitomycin | Candida albicans | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
377,
24,
200
]
],
[
[
377,
24,
1683
],
[
1683,
24,
200
]
],
[
[
377,
25,
976
],
[
976,
24,
200
]
],
[
[
377,
24,
738
],
[
738,
6... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Mitomycin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ma... |
DB00604 | DB06176 | 1,425 | 1,342 | [
"DDInter385",
"DDInter1616"
] | Cisapride | Romidepsin | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
1425,
25,
1342
]
],
[
[
1425,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
1425,
25,
336
],
[
336,
24,
1342
]
],
[
[
1425,
25,
1616
],
[
1616... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamet... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Cisapride may lead to a major life threatening interaction when taken with Nifedipine and Nifedipine may ... |
DB01030 | DB14811 | 869 | 385 | [
"DDInter1835",
"DDInter979"
] | Topotecan | Isatuximab | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
869,
24,
385
]
],
[
[
869,
24,
1362
],
[
1362,
24,
385
]
],
[
[
869,
63,
377
],
[
377,
24,
385
]
],
[
[
869,
64,
1555
],
[
1555,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may... |
DB00031 | DB01404 | 20 | 757 | [
"DDInter1764",
"DDInter820"
] | Tenecteplase | Ginseng | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
20,
24,
757
]
],
[
[
20,
24,
578
],
[
578,
63,
757
]
],
[
[
20,
25,
553
],
[
553,
24,
757
]
],
[
[
20,
25,
256
],
[
256,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Tenecteplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may c... |
DB00215 | DB00673 | 1,230 | 723 | [
"DDInter388",
"DDInter112"
] | Citalopram | Aprepitant | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Minor | 0 | [
[
[
1230,
23,
723
]
],
[
[
1230,
6,
7950
],
[
7950,
45,
723
]
],
[
[
1230,
21,
28890
],
[
28890,
60,
723
]
],
[
[
1230,
1,
318
],
[
318,
... | [
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Citalopram (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Citalopram (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Citalopram (Compound) resembles Escitalopram (Compound) and Es
Citalopram may lead to ... |
DB01059 | DB01259 | 956 | 392 | [
"DDInter1313",
"DDInter1024"
] | Norfloxacin | Lapatinib | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
956,
24,
392
]
],
[
[
956,
6,
8374
],
[
8374,
45,
392
]
],
[
[
956,
21,
28852
],
[
28852,
60,
392
]
],
[
[
956,
62,
112
],
[
112,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Norfloxacin (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00820 | DB08899 | 402 | 129 | [
"DDInter1736",
"DDInter649"
] | Tadalafil | Enzalutamide | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
402,
24,
129
]
],
[
[
402,
24,
918
],
[
918,
1,
129
]
],
[
[
402,
6,
8374
],
[
8374,
45,
129
]
],
[
[
402,
21,
28703
],
[
28703,
... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Tadalafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Tadalafil (Compound) causes Pruritus (Side Effect) and Pruri... |
DB00850 | DB01246 | 1,630 | 820 | [
"DDInter1432",
"DDInter45"
] | Perphenazine | Alimemazine | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1630,
35,
820
]
],
[
[
1630,
1,
11237
],
[
11237,
40,
820
]
],
[
[
1630,
35,
104
],
[
104,
40,
820
]
],
[
[
1630,
35,
401
],
[
401,
... | [
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
],
... | Perphenazine (Compound) resembles Alimemazine (Compound) and
Perphenazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Alimemazine (Compound)
Perphenazine (Compound) resembles Methdilazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseas... |
DB00270 | DB11348 | 1,428 | 1,065 | [
"DDInter993",
"DDInter279"
] | Isradipine | Calcium Phosphate | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1428,
24,
1065
]
],
[
[
1428,
1,
336
],
[
336,
24,
1065
]
],
[
[
1428,
40,
854
],
[
854,
24,
1065
]
],
[
[
1428,
1,
336
],
[
336,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a ... | Isradipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Isradipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Calc... |
DB04896 | DB08875 | 901 | 1,618 | [
"DDInter1220",
"DDInter262"
] | Milnacipran | Cabozantinib | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
901,
24,
1618
]
],
[
[
901,
24,
384
],
[
384,
63,
1618
]
],
[
[
901,
63,
480
],
[
480,
24,
1618
]
],
[
[
901,
40,
41
],
[
41,
63... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Fo... |
DB00418 | DB00662 | 536 | 717 | [
"DDInter1650",
"DDInter1873"
] | Secobarbital | Trimethobenzamide | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
536,
24,
717
]
],
[
[
536,
21,
28762
],
[
28762,
60,
717
]
],
[
[
536,
63,
1594
],
[
1594,
24,
717
]
],
[
[
536,
24,
13
],
[
13,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Secobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect... | Secobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00682 | DB11767 | 126 | 1,583 | [
"DDInter1951",
"DDInter1643"
] | Warfarin | Sarilumab | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
126,
24,
1583
]
],
[
[
126,
63,
1461
],
[
1461,
23,
1583
]
],
[
[
126,
63,
362
],
[
362,
24,
1583
]
],
[
[
126,
24,
890
],
[
890,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"V... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may ca... |
DB00813 | DB01181 | 704 | 1,532 | [
"DDInter722",
"DDInter906"
] | Fentanyl | Ifosfamide | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
704,
24,
1532
]
],
[
[
704,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
704,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
704,
40,
307
],
[
307,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Fentanyl",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Fentanyl (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Fentanyl (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Fentanyl (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limi... |
DB01142 | DB06016 | 1,264 | 1,508 | [
"DDInter593",
"DDInter300"
] | Doxepin | Cariprazine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1264,
24,
1508
]
],
[
[
1264,
24,
1637
],
[
1637,
24,
1508
]
],
[
[
1264,
25,
1593
],
[
1593,
63,
1508
]
],
[
[
1264,
63,
1242
],
[
12... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Doxepin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a... |
DB01155 | DB05294 | 872 | 1,069 | [
"DDInter813",
"DDInter1917"
] | Gemifloxacin | Vandetanib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
872,
25,
1069
]
],
[
[
872,
21,
29343
],
[
29343,
60,
1069
]
],
[
[
872,
62,
112
],
[
112,
23,
1069
]
],
[
[
872,
24,
659
],
[
659,
... | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Blood creatinine increased"
],
[
"Blood creatinine increased",
"{u... | Gemifloxacin (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit ... |
DB00697 | DB06788 | 876 | 1,616 | [
"DDInter1821",
"DDInter864"
] | Tizanidine | Histrelin | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
876,
24,
1616
]
],
[
[
876,
23,
112
],
[
112,
23,
1616
]
],
[
[
876,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
876,
24,
927
],
[
927,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Tizanidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romid... |
DB00804 | DB00850 | 1,507 | 1,630 | [
"DDInter543",
"DDInter1432"
] | Dicyclomine | Perphenazine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1507,
24,
1630
]
],
[
[
1507,
63,
252
],
[
252,
40,
1630
]
],
[
[
1507,
24,
673
],
[
673,
40,
1630
]
],
[
[
1507,
21,
29232
],
[
29232... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphenazine... |
DB00794 | DB01142 | 759 | 1,264 | [
"DDInter1521",
"DDInter593"
] | Primidone | Doxepin | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
759,
24,
1264
]
],
[
[
759,
24,
401
],
[
401,
24,
1264
]
],
[
[
759,
63,
832
],
[
832,
24,
1264
]
],
[
[
759,
24,
649
],
[
649,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tri... |
DB00046 | DB00294 | 1,179 | 1,336 | [
"DDInter940",
"DDInter701"
] | Insulin lispro | Etonogestrel | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Moderate | 1 | [
[
[
1179,
24,
1336
]
],
[
[
1179,
24,
566
],
[
566,
1,
1336
]
],
[
[
1179,
24,
1561
],
[
1561,
40,
1336
]
],
[
[
1179,
24,
1130
],
[
1130,... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Etonogestrel (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles ... |
DB01009 | DB09472 | 935 | 1,383 | [
"DDInter1009",
"DDInter1693"
] | Ketoprofen | Sodium sulfate | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
935,
24,
1383
]
],
[
[
935,
40,
886
],
[
886,
24,
1383
]
],
[
[
935,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
935,
25,
1618
],
[
1618,
... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Ketorolac"
],
[
"Ketorolac",
"{u} may cause a moder... | Ketoprofen (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderat... |
DB00397 | DB00476 | 1,466 | 109 | [
"DDInter1458",
"DDInter608"
] | Phenylpropanolamine | Duloxetine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Major | 2 | [
[
[
1466,
25,
109
]
],
[
[
1466,
63,
847
],
[
847,
1,
109
]
],
[
[
1466,
25,
758
],
[
758,
1,
109
]
],
[
[
1466,
6,
7950
],
[
7950,
... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Duloxetine (Compound)
Phenylpropanolamine may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compo... |
DB00214 | DB11130 | 1,028 | 407 | [
"DDInter1836",
"DDInter1344"
] | Torasemide | Opium | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1028,
24,
407
]
],
[
[
1028,
24,
104
],
[
104,
24,
407
]
],
[
[
1028,
23,
1347
],
[
1347,
24,
407
]
],
[
[
1028,
64,
1314
],
[
1314,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Torasemide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidog... |
DB00476 | DB01390 | 109 | 1,117 | [
"DDInter608",
"DDInter1683"
] | Duloxetine | Sodium bicarbonate | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
109,
23,
1117
]
],
[
[
109,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
109,
63,
1018
],
[
1018,
23,
1117
]
],
[
[
109,
23,
1127
],
[
1127... | [
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is ca... | Duloxetine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Sod... |
DB08901 | DB09068 | 1,468 | 1,427 | [
"DDInter1492",
"DDInter1948"
] | Ponatinib | Vortioxetine | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1468,
24,
1427
]
],
[
[
1468,
24,
1320
],
[
1320,
63,
1427
]
],
[
[
1468,
64,
25
],
[
25,
24,
1427
]
],
[
[
1468,
63,
1220
],
[
1220,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ponatinib may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause ... |
DB00539 | DB11718 | 11 | 927 | [
"DDInter1837",
"DDInter640"
] | Toremifene | Encorafenib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
11,
25,
927
]
],
[
[
11,
23,
112
],
[
112,
23,
927
]
],
[
[
11,
24,
720
],
[
720,
24,
927
]
],
[
[
11,
64,
216
],
[
216,
24,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB10429 | DB12498 | 200 | 76 | [
"DDInter282",
"DDInter1238"
] | Candida albicans | Mogamulizumab | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
200,
24,
76
]
],
[
[
200,
63,
1531
],
[
1531,
24,
76
]
],
[
[
200,
24,
738
],
[
738,
24,
76
]
],
[
[
200,
24,
676
],
[
676,
64,
... | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"... | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Nira... |
DB09104 | DB11703 | 286 | 405 | [
"DDInter1118",
"DDInter9"
] | Magnesium hydroxide | Acalabrutinib | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
286,
24,
405
]
],
[
[
286,
24,
982
],
[
982,
63,
405
]
],
[
[
286,
63,
1230
],
[
1230,
24,
405
]
],
[
[
286,
24,
460
],
[
460,
2... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosid... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00539 | DB00951 | 11 | 1,072 | [
"DDInter1837",
"DDInter986"
] | Toremifene | Isoniazid | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
11,
24,
1072
]
],
[
[
11,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
11,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
11,
25,
1220
],
[
1220,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Toremifene (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Toremifene may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause ... |
DB09331 | DB11627 | 745 | 1,367 | [
"DDInter478",
"DDInter860"
] | Daratumumab | Hepatitis B Vaccine (Recombinant) | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
745,
24,
1367
]
],
[
[
745,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
745,
63,
259
],
[
259,
24,
1367
]
],
[
[
745,
24,
738
],
[
738,
... | [
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]... | Daratumumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept ... |
DB01232 | DB04845 | 1,327 | 309 | [
"DDInter1640",
"DDInter1001"
] | Saquinavir | Ixabepilone | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
1327,
24,
309
]
],
[
[
1327,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1327,
21,
28736
],
[
28736,
60,
309
]
],
[
[
1327,
63,
1419
],
[
1419... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Saquinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Saquinavir (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and ... |
DB00342 | DB15093 | 1,181 | 1,654 | [
"DDInter1770",
"DDInter1698"
] | Terfenadine | Somapacitan | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1181,
24,
1654
]
],
[
[
1181,
25,
351
],
[
351,
24,
1654
]
],
[
[
1181,
24,
1010
],
[
1010,
24,
1654
]
],
[
[
1181,
23,
1387
],
[
1387... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocic... | Terfenadine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cau... |
DB00275 | DB00443 | 217 | 251 | [
"DDInter1330",
"DDInter195"
] | Olmesartan | Betamethasone | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
217,
24,
251
]
],
[
[
217,
24,
617
],
[
617,
40,
251
]
],
[
[
217,
24,
870
],
[
870,
1,
251
]
],
[
[
217,
21,
29081
],
[
29081,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betametha... |
DB00934 | DB09065 | 413 | 760 | [
"DDInter1124",
"DDInter424"
] | Maprotiline | Cobicistat | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
413,
24,
760
]
],
[
[
413,
24,
1374
],
[
1374,
23,
760
]
],
[
[
413,
25,
868
],
[
868,
24,
760
]
],
[
[
413,
24,
609
],
[
609,
2... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Maprotiline may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may ca... |
DB00945 | DB01244 | 1,479 | 762 | [
"DDInter20",
"DDInter192"
] | Acetylsalicylic acid | Bepridil | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Moderate | 1 | [
[
[
1479,
24,
762
]
],
[
[
1479,
6,
4973
],
[
4973,
45,
762
]
],
[
[
1479,
21,
28789
],
[
28789,
60,
762
]
],
[
[
1479,
24,
578
],
[
578,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by ... | Acetylsalicylic acid (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Bepridil (Compound)
Acetylsalicylic acid (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Bepridil (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerb... |
DB12001 | DB12500 | 564 | 283 | [
"DDInter7",
"DDInter714"
] | Abemaciclib | Fedratinib | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
564,
24,
283
]
],
[
[
564,
63,
351
],
[
351,
23,
283
]
],
[
[
564,
63,
1419
],
[
1419,
24,
283
]
],
[
[
564,
25,
676
],
[
676,
6... | [
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib... |
DB06595 | DB08882 | 1,491 | 1,281 | [
"DDInter1214",
"DDInter1070"
] | Midostaurin | Linagliptin | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1491,
24,
1281
]
],
[
[
1491,
63,
1002
],
[
1002,
1,
1281
]
],
[
[
1491,
64,
651
],
[
651,
24,
1281
]
],
[
[
1491,
63,
1052
],
[
1052,... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Midostaurin may lead to a major life threatening interaction when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerb... |
DB00477 | DB01362 | 216 | 497 | [
"DDInter363",
"DDInter960"
] | Chlorpromazine | Iohexol | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
216,
25,
497
]
],
[
[
216,
21,
28681
],
[
28681,
60,
497
]
],
[
[
216,
63,
999
],
[
999,
25,
497
]
],
[
[
216,
24,
1264
],
[
1264,
... | [
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is ... | Chlorpromazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when ta... |
DB00471 | DB01045 | 201 | 463 | [
"DDInter1242",
"DDInter1590"
] | Montelukast | Rifampicin | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
201,
24,
463
]
],
[
[
201,
24,
690
],
[
690,
40,
463
]
],
[
[
201,
6,
17752
],
[
17752,
45,
463
]
],
[
[
201,
63,
1101
],
[
1101,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Montelukast (Compound) binds SLCO2B1 (Gene) and SLCO2B1 (Gene) is bound by Rifampicin (Compound)
Montelukast may cause a moderate interaction that could exacerba... |
DB00515 | DB05273 | 589 | 507 | [
"DDInter387",
"DDInter1638"
] | Cisplatin | Samarium (153Sm) lexidronam | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
589,
25,
507
]
],
[
[
589,
24,
789
],
[
789,
24,
507
]
],
[
[
589,
24,
270
],
[
270,
63,
507
]
],
[
[
589,
24,
110
],
[
110,
64,... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizu... |
DB00197 | DB00443 | 1,324 | 251 | [
"DDInter1881",
"DDInter195"
] | Troglitazone | Betamethasone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
1324,
24,
251
]
],
[
[
1324,
24,
870
],
[
870,
1,
251
]
],
[
[
1324,
24,
1486
],
[
1486,
40,
251
]
],
[
[
1324,
23,
1103
],
[
1103,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound)... |
DB00773 | DB12500 | 896 | 283 | [
"DDInter702",
"DDInter714"
] | Etoposide | Fedratinib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
896,
24,
283
]
],
[
[
896,
24,
351
],
[
351,
23,
283
]
],
[
[
896,
24,
327
],
[
327,
24,
283
]
],
[
[
896,
63,
1419
],
[
1419,
2... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir... |
DB05812 | DB14840 | 1,374 | 861 | [
"DDInter8",
"DDInter1601"
] | Abiraterone | Ripretinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1374,
24,
861
]
],
[
[
1374,
25,
351
],
[
351,
24,
861
]
],
[
[
1374,
24,
214
],
[
214,
24,
861
]
],
[
[
1374,
63,
392
],
[
392,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocicl... | Abiraterone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may ... |
DB00006 | DB04896 | 942 | 901 | [
"DDInter217",
"DDInter1220"
] | Bivalirudin | Milnacipran | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
942,
24,
901
]
],
[
[
942,
24,
41
],
[
41,
1,
901
]
],
[
[
942,
25,
405
],
[
405,
63,
901
]
],
[
[
942,
25,
500
],
[
500,
24,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Bivalirudin may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that c... |
DB00328 | DB08896 | 831 | 292 | [
"DDInter921",
"DDInter1576"
] | Indomethacin | Regorafenib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
831,
25,
292
]
],
[
[
831,
6,
6017
],
[
6017,
45,
292
]
],
[
[
831,
21,
29276
],
[
29276,
60,
292
]
],
[
[
831,
63,
1560
],
[
1560,
... | [
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Indomethacin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Re... | Indomethacin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Indomethacin (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Regorafenib (Compound)
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspa... |
DB01015 | DB09080 | 1,247 | 144 | [
"DDInter1724",
"DDInter1331"
] | Sulfamethoxazole | Olodaterol | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Minor | 0 | [
[
[
1247,
23,
144
]
],
[
[
1247,
23,
1011
],
[
1011,
24,
144
]
],
[
[
1247,
62,
11
],
[
11,
24,
144
]
],
[
[
1247,
23,
823
],
[
823,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olodaterol"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
],
... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene an... |
DB00553 | DB01021 | 92 | 674 | [
"DDInter1177",
"DDInter1861"
] | Methoxsalen | Trichlormethiazide | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
92,
24,
674
]
],
[
[
92,
24,
1014
],
[
1014,
40,
674
]
],
[
[
92,
24,
178
],
[
178,
1,
674
]
],
[
[
92,
63,
323
],
[
323,
40,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Tric... |
DB00554 | DB11095 | 1,027 | 235 | [
"DDInter1478",
"DDInter505"
] | Piroxicam | Desirudin | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
1027,
25,
235
]
],
[
[
1027,
24,
578
],
[
578,
24,
235
]
],
[
[
1027,
24,
738
],
[
738,
63,
235
]
],
[
[
1027,
63,
1061
],
[
1061,
... | [
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib ... |
DB00087 | DB01254 | 599 | 1,213 | [
"DDInter41",
"DDInter484"
] | Alemtuzumab | Dasatinib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
599,
24,
1213
]
],
[
[
599,
24,
1136
],
[
1136,
63,
1213
]
],
[
[
599,
24,
563
],
[
563,
24,
1213
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Gancic... |
DB05676 | DB11760 | 1,513 | 119 | [
"DDInter111",
"DDInter1742"
] | Apremilast | Talazoparib | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1513,
24,
119
]
],
[
[
1513,
24,
1623
],
[
1623,
24,
119
]
],
[
[
1513,
24,
214
],
[
214,
63,
119
]
],
[
[
1513,
24,
1623
],
[
1623,
... | [
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
... | Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatin... |
DB00280 | DB00687 | 494 | 870 | [
"DDInter575",
"DDInter747"
] | Disopyramide | Fludrocortisone | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
494,
24,
870
]
],
[
[
494,
24,
1220
],
[
1220,
40,
870
]
],
[
[
494,
21,
29180
],
[
29180,
60,
870
]
],
[
[
494,
24,
688
],
[
688,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Disopyramide (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fludrocortisone (Compound)
Di... |
DB00344 | DB11978 | 1,302 | 124 | [
"DDInter1543",
"DDInter822"
] | Protriptyline | Glasdegib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1302,
24,
124
]
],
[
[
1302,
23,
112
],
[
112,
23,
124
]
],
[
[
1302,
63,
475
],
[
475,
24,
124
]
],
[
[
1302,
24,
79
],
[
79,
2... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Protriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Morphine and M... |
DB00365 | DB06772 | 839 | 310 | [
"DDInter842",
"DDInter259"
] | Grepafloxacin | Cabazitaxel | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
839,
24,
310
]
],
[
[
839,
24,
973
],
[
973,
24,
310
]
],
[
[
839,
25,
868
],
[
868,
63,
310
]
],
[
[
839,
23,
869
],
[
869,
24,... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Grepafloxacin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib m... |
DB01377 | DB04868 | 1,283 | 478 | [
"DDInter1119",
"DDInter1293"
] | Magnesium oxide | Nilotinib | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1283,
24,
478
]
],
[
[
1283,
23,
1468
],
[
1468,
63,
478
]
],
[
[
1283,
24,
809
],
[
809,
62,
478
]
],
[
[
1283,
25,
1459
],
[
1459,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Raltegravir and ... |
DB00344 | DB01142 | 1,302 | 1,264 | [
"DDInter1543",
"DDInter593"
] | Protriptyline | Doxepin | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1302,
24,
1264
]
],
[
[
1302,
24,
401
],
[
401,
24,
1264
]
],
[
[
1302,
40,
11355
],
[
11355,
1,
1264
]
],
[
[
1302,
24,
649
],
[
649,... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Protriptyline (Compound) resembles Indecainide (Compound) and Indecainide (Compound) resembles Doxepin (Comp... |
DB01156 | DB01230 | 593 | 795 | [
"DDInter252",
"DDInter1416"
] | Bupropion | Pemoline | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Major | 2 | [
[
[
593,
25,
795
]
],
[
[
593,
25,
1613
],
[
1613,
63,
795
]
],
[
[
593,
24,
1662
],
[
1662,
63,
795
]
],
[
[
593,
63,
305
],
[
305,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pemoline"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta... | Bupropion may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid ... |
DB00382 | DB00675 | 62 | 888 | [
"DDInter1734",
"DDInter1744"
] | Tacrine | Tamoxifen | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
62,
24,
888
]
],
[
[
62,
63,
1594
],
[
1594,
40,
888
]
],
[
[
62,
24,
543
],
[
543,
63,
888
]
],
[
[
62,
24,
1376
],
[
1376,
64,... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Do... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Tamoxifen (Compound)
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacer... |
DB00040 | DB00598 | 27 | 1,523 | [
"DDInter827",
"DDInter1013"
] | Glucagon | Labetalol | Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Minor | 0 | [
[
[
27,
23,
1523
]
],
[
[
27,
23,
126
],
[
126,
62,
1523
]
],
[
[
27,
23,
699
],
[
699,
5,
11590
],
[
11590,
44,
1523
]
],
[
[
27,
2... | [
[
[
"Glucagon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
]
],
[
[
"Glucagon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfar... | Glucagon may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Labetalol
Glucagon may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol (Compound) treat... |
DB00393 | DB05679 | 854 | 1,683 | [
"DDInter1295",
"DDInter1907"
] | Nimodipine | Ustekinumab | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
854,
24,
1683
]
],
[
[
854,
24,
1093
],
[
1093,
63,
1683
]
],
[
[
854,
1,
409
],
[
409,
24,
1683
]
],
[
[
854,
24,
1053
],
[
1053,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Nimodipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that coul... |
DB00414 | DB14006 | 590 | 972 | [
"DDInter16",
"DDInter370"
] | Acetohexamide | Choline salicylate | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
590,
24,
972
]
],
[
[
590,
23,
660
],
[
660,
23,
972
]
],
[
[
590,
24,
1573
],
[
1573,
24,
972
]
],
[
[
590,
63,
176
],
[
176,
2... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
... | Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Choline salicylate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Prednis... |
DB00712 | DB05528 | 1,274 | 1,070 | [
"DDInter763",
"DDInter1228"
] | Flurbiprofen | Mipomersen | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1274,
25,
1070
]
],
[
[
1274,
37,
292
],
[
292,
64,
1070
]
],
[
[
1274,
63,
1512
],
[
1512,
25,
1070
]
],
[
[
1274,
24,
384
],
[
384,
... | [
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening in... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Flurbiprofen may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Flurbiprofen may cause a mode... |
DB00968 | DB01592 | 1,551 | 1,596 | [
"DDInter1185",
"DDInter975"
] | Methyldopa | Iron | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Moderate | 1 | [
[
[
1551,
24,
1596
]
],
[
[
1551,
21,
29161
],
[
29161,
60,
1596
]
],
[
[
1551,
1,
1191
],
[
1191,
24,
1596
]
],
[
[
1551,
21,
29161
],
[
... | [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Methyldopa",
"{u} (Compound) causes {v} (Side Effect)",
"Nasal congestion"
],
[
"Nasal congestion",
"{u} (Side Effect)... | Methyldopa (Compound) causes Nasal congestion (Side Effect) and Nasal congestion (Side Effect) is caused by Iron (Compound)
Methyldopa (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Iron
Methyldopa (Compound) causes Nasal congestion ... |
DB00502 | DB04868 | 1,300 | 478 | [
"DDInter853",
"DDInter1293"
] | Haloperidol | Nilotinib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
1300,
25,
478
]
],
[
[
1300,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1300,
18,
2183
],
[
2183,
57,
478
]
],
[
[
1300,
21,
28963
],
[
28963... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Niloti... | Haloperidol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Haloperidol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Haloperidol (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Halope... |
DB08880 | DB11979 | 1,510 | 1,320 | [
"DDInter1771",
"DDInter625"
] | Teriflunomide | Elagolix | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
1510,
25,
1320
]
],
[
[
1510,
64,
168
],
[
168,
23,
1320
]
],
[
[
1510,
62,
608
],
[
608,
23,
1320
]
],
[
[
1510,
24,
1612
],
[
1612,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{... | Teriflunomide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a ... |
DB05578 | DB06209 | 330 | 256 | [
"DDInter1566",
"DDInter1508"
] | Ramucirumab | Prasugrel | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
330,
25,
256
]
],
[
[
330,
63,
901
],
[
901,
24,
256
]
],
[
[
330,
24,
1427
],
[
1427,
63,
256
]
],
[
[
330,
64,
1479
],
[
1479,
... | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacip... | Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and V... |
DB00673 | DB12457 | 723 | 1,180 | [
"DDInter112",
"DDInter1598"
] | Aprepitant | Rimegepant | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
723,
24,
1180
]
],
[
[
723,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
723,
63,
1419
],
[
1419,
24,
1180
]
],
[
[
723,
24,
283
],
[
283,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib m... |
DB00398 | DB00450 | 79 | 78 | [
"DDInter1702",
"DDInter603"
] | Sorafenib | Droperidol | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Major | 2 | [
[
[
79,
25,
78
]
],
[
[
79,
25,
1300
],
[
1300,
40,
78
]
],
[
[
79,
25,
1568
],
[
1568,
1,
78
]
],
[
[
79,
21,
28921
],
[
28921,
60,... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} (... | Sorafenib may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol (Compound) resembles Droperidol (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Pimozide and Pimozide (Compound) resembles Droperidol (Compound)
Sorafenib (Compound) causes Dizzin... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.